Solid Biosciences Inc. (SLDB)

2.3000 -0.1400 (-5.74%) At close: 4:00PM EDT

Solid Biosciences Inc.

141 Portland Street
Fifth Floor
Cambridge, MA 02139
United States
617 337 4680
http://www.solidbio.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 121

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Ilan Ganot	Co-founder, Pres, CEO & Director	713.05k	N/A	1974
Mr. Matthew Bennett Arnold	Co-Founder & Independent Director	42.5k	N/A	1970
Ms. Annie Ganot	Co-Founder & Director of Patient Advocacy	N/A	N/A	N/A
Ms. Jennifer Ziolkowski CPA, CPA	CFO & Treasurer	N/A	N/A	1975
Dr. Joel Solomon Zev Schneider	Chief Technology Officer	N/A	N/A	1985

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Solid Biosciences Inc.’s ISS Governance QualityScore as of December 9, 2019 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.